Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
|Articles|April 2, 2021
- Pharmaceutical Technology-04-02-2021
- Volume 45
- Issue 4
Peristaltic Pump for Biopharmaceutical Applications
High Purity New England launched the VerderFlex Vantage 5000 peristaltic pump for medium flow at low to medium pressures in biopharmaceutical applications.
High Purity New England launched the VerderFlex Vantage 5000 peristaltic pump for medium flow at low to medium pressures in biopharmaceutical applications.
With a flow rate from 70 µL/min up to 6600 mL/min, the pump includes advanced record keeping and control options, with accuracy within 1% and the option to store up to 30 different programs. The pump also features touch-screen technology that gives users access to downloadable jobs, pump histories, and the ability to remotely monitor the pump through the Verderflex app. Additonally, the touchscreen feature comes equipped with icon-based programming, real-time stamped events, and the option to onboard storage via a USB.
Articles in this issue
over 5 years ago
Advanced Manufacturing Technologies Shift Outside the Boxover 5 years ago
Reshoring and Expanding API Manufacturing Capabilitiesover 5 years ago
Balancing the Art and Science of Topical Drug Formulationover 5 years ago
Focusing on Accelerated Formulation Strategiesover 5 years ago
Understanding the Impact of Annex 1 on Isolator Operationover 5 years ago
Blocking the Threat of Counterfeit Medicinesover 5 years ago
Limitations and Advances in Dissolution TestingRelated to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
Our Biggest Takeaways From AAPS PharmSci 360
3
France Remains One of Europe’s Leading Biotech Funding Hubs
4
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
5